🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

206 results for “Glaxo” Clear

  1. A study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK4771261 in healthy participants and participants with autosomal dominant polycystic kidney disease.

    GlaxoSmithKline

    Kidney Disease

    phase 1 other active

    1 trial

  2. A study to investigate the pharmacokinetics of a combined oral contraceptive when given alone and in combination with GSK3036656 in female participants of non-childbearing potential aged 18 to 65 years of age

    GlaxoSmithKline

    Tuberculosis

    phase 1 other active

    1 trial

  3. A study to investigate the safety and pharmacological effect of a single intravenous infusion of GSK2857914 in male and female participants aged 18 to 75 with moderate to severe systemic lupus erythematosus

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  4. A study to investigate the safety and tolerability of dostarlimab in adult participants with chronic HBV infection on nucleos(t)ide analogue (NA) treatment

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 1 other active

    1 trial

  5. A study to investigate the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of a CD19/CD20 T-cell engager in participants with B-cell driven ARD.

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  6. A study to investigate the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of a single subcutaneous dose of GSK4771261 in healthy participants aged 25 to 55 years of age inclusive

    GlaxoSmithKline

    Autosomal Dominant Polycystic Kidney Disease

    phase 1 other active

    1 trial

  7. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Lamotrigine Dispersible Tablets BP 100 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Lamictal (Lamotrigine) Dispersible Tablets 100 mg, Manufactured by: Delpharm Poznaÿ – Poland & Registered and Imported by: GlaxoSmithKline Brasil Ltda, in healthy adult, human subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    Bipolar disorder, Epilepsy

    phase 1 other active

    1 trial

  8. Chloroquine

    GlaxoSmithKline

    Malaria

    phase 1 small molecule completed

    1 trial

  9. Daprodustat 2 mg tablet

    GlaxoSmithKline

    Anaemia

    phase 1 small molecule completed

    1 trial

  10. First time in human (FTIH) study to investigate the safety and preliminary activity of GSK5533524 alone or in combination in adult participants with advanced solid tumors

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  11. GSK2269557 ELLIPTA DPI

    GlaxoSmithKline

    Pulmonary Disease, Chronic Obstructive

    phase 1 small molecule completed

    1 trial

  12. GSK2879552

    GlaxoSmithKline

    Leukaemia, Myelocytic, Acute

    phase 1 small molecule terminated

    1 trial

  13. GSK525762

    GlaxoSmithKline

    Solid Tumours

    phase 1 small molecule terminated

    1 trial

  14. GSK5533524

    GlaxoSmithKline

    Neoplasms

    phase 1 small molecule active

    1 trial

  15. Lamivudine

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 1 small molecule completed

    1 trial

  16. New formulation

    GlaxoSmithKline

    Herpes Labialis

    phase 1 small molecule completed

    1 trial

  17. Pazopanib

    GlaxoSmithKline

    Neoplasms, Colorectal

    phase 1 small molecule completed

    1 trial

  18. Phase 1, Open-Label, single arm (Non-comparator) Study to Evaluate the Pharmacokinetics and Safety of a Single Dose of Oral Gepotidacin in Addition to Antibacterial Standard of Care in Pediatric Participants from 2 to less than 12 years of age with a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis with Antibiotics

    GlaxoSmithKline

    Urinary Tract Infections

    phase 1 other active

    1 trial

  19. Poliorix

    GlaxoSmithKline

    Poliomyelitis

    phase 1 mab completed

    1 trial

  20. Prednisolone

    GlaxoSmithKline

    Pulmonary Disease, Chronic Obstructive

    phase 1 small molecule completed

    1 trial

  21. SB-659032

    GlaxoSmithKline

    Atherosclerosis

    phase 1 small molecule completed

    1 trial

  22. Test Montelukast

    GlaxoSmithKline

    Respiratory Disorders

    phase 1 small molecule completed

    1 trial

  23. Zejula 100 mg film-coated tablets, Zejula 100 mg film-coated tablets, JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Solid Tumours

    phase 1 small molecule active

    1 trial

  24. Amoxicillin/clavulanate

    GlaxoSmithKline

    Focal Infection, Dental

    approved small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources